Skye extends EHT deal outside date to Nov 15, receives $700K loan from EHT

Skye Bioscience, Inc.

Third Amendment extends outside date for acquisition of Emerald Health Therapeutics to November 15, 2022, subject to possible 15-day extension.
EHT loans Skye $700,000 at 12% interest (reduces to 5% upon deal closing), due earlier of Oct 17, 2023 or Dec 31, 2022 if deal terminated.
Proceeds from loan to be used for general working capital; waiver obtained from Emerald Health Sciences for incurrence of debt.
Stockholders and Supreme Court of British Columbia have approved the arrangement; closing expected early to mid-November.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.